GlassScriptPhysician profile
Cynthia A Self
NPI 1275521650
$3,156.03
in general payments reported to CMS, 2019-2025
18 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $144 · 2021: $251 · 2022: $373 · 2023: $592 · 2024: $971 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782 · Education: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.73 |
| Education | $470.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,096.22 | 2022-2025 | Acthar |
| Steris Corporation | $275.00 | 2024 | |
| Aerie Pharmaceuticals, INC. | $246.85 | 2019-2021 | |
| Abbvie INC. | $181.57 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $181.26 | 2022-2025 | Miebo, Envista Mx60 Iol, Vyzulta |
| Oyster Point Pharma, INC. | $168.86 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $168.71 | 2022-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Allergan, INC. | $133.15 | 2020-2021 | |
| Dompe US, INC. | $121.72 | 2021-2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $100.66 | 2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $96.40 | 2019-2024 | Cequa |
| Amgen INC. | $79.96 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $66.79 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $62.21 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $56.42 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $55.59 | 2021-2025 | Idosetr |
| Biotissue Holdings INC. | $48.80 | 2024-2025 | |
| Horizon Therapeutics Plc | $15.86 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Self listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.